Asset profile
Cariprazine (Chengdu Kanghong)
Small molecule
Evidence outlook · registrational
Schizophrenia: registrational readout pending
Its supporting mid-stage evidence has not yet been graded on this platform. The registry's posted readout date (2026-06) has passed without a status update. Check News for topline announcements.
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. Pick an indication; Research unlocks the trials, endpoints, key results and grades.
Competitive landscape
64 competitors in this universe: 4 direct rivals (same mechanism and indication), 0 same-class, 60 same-indication; 37 further along in development.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials |
|---|---|---|---|---|---|
| Cariprazine (Chengdu Kanghong): this drug | Phase 3 | Small molecule | Dopamine D3/D2 receptor (partial agonist) | ||
| Cariprazine (Vraylar) | Approved | Small molecule | Dopamine D3/D2 receptor (partial agonist) | ||
| QLM1016 | Phase 3 | Small molecule | Dopamine D3/D2 and serotonin 5-HT1A receptors (partial agonist), Dopamine D3/D2 receptor (partial agonist) | ||
| Cariprazine Long-Acting Injection (Mapi Pharma) | Phase 1/2 | Small molecule | Dopamine D3/D2 receptor (partial agonist) | ||
| JX11502MA | Phase 1/2 | Small molecule | Dopamine D3/D2 receptor (partial agonist) | ||
| Aripiprazole (Abilify Maintena) | Approved | Small molecule | Dopamine D2 and serotonin 5-HT1A receptors (partial agonist), Dopamine D2/D3 and serotonin 5-HT1A receptor, Dopamine D2 receptor (partial agonist) | ||
| Aripiprazole (Abilify MyCite) | Approved | Combination | Dopamine D2 and serotonin 5-HT1A receptors (partial agonist); serotonin 5-HT2A receptor (antagonist) | ||
| Aripiprazole (Abilify) | Approved | Small molecule | Dopamine D2/D3 and serotonin 5-HT1A receptor | ||
| Aripiprazole Lauroxil (Aristada Initio) | Approved | Small molecule | Dopamine D2/D3 and serotonin 5-HT1A receptor | ||
| Aripiprazole Lauroxil (Aristada) | Approved | Small molecule | Dopamine D2/D3 and serotonin 5-HT1A receptor | ||
| Asenapine | Approved | Small molecule | Dopamine D2 and serotonin 5-HT2A receptors (antagonist) | ||
| Brexpiprazole (Rexulti) | Approved | Small molecule | Dopamine D2/D3 and serotonin 5-HT1A receptor | ||
| Clozapine | Approved | Small molecule | Dopamine D2 and serotonin 5-HT2A receptors (antagonist) | ||
| Dexmedetomidine (Igalmi) | Approved | — | — | ||
| Dexmedetomidine (Igalmi) | Approved | Small molecule | Alpha-2 adrenergic receptor (agonist) | ||
| Fazaclo | Approved | Small molecule | Dopamine D2 and serotonin 5-HT2A receptors (antagonist) |
…and 49 more. Research shows the complete landscape.
Unlock the full comparison
Research adds each competitor's evidence grade and sourced trial results, aligned per race, so you can see who actually has the data.
Compare head-to-head
Upcoming events
No upcoming readouts on record for this asset.
All registered studies
Every ClinicalTrials.gov study of this drug's own program, grouped by indication and phase. Research unlocks the studies themselves: titles, statuses, dates and featured-trial cross-links.